亮点速览创新点：本研究首次通过村医主导，结合移动健康（mHealth）技术，开展全面的心血管风险管理，显著降低农村居民10年动脉粥样硬化心血管病（ASCVD）风险。效果显著：干预组10年ASCVD风险从18.0%下降至11.7%，对照组仅下降至13.6%；干预组血压、血糖控制及不良行为改变均优于对照。人群差异：男性、非农职业、低收入及高风险人群获益更大，表明该策略对社会弱势群体同样有效及具推广潜力。研究概要中国农村的心血管疾病负担巨大且日益加重，如何有效降低这些高危人群的心血管风险成为公共卫生的紧迫问题。2025年4月9日，发表于《British Medical Journal》(BMJ)的一项由李希博士团队牵头的多中心cluster随机对照试验（SMARTER研究）对127个中国农村村庄共4533名参与者，验证了以村医为骨干、结合移动健康技术的健康管理干预策略在心血管病初级预防中的有效性。该策略涵盖风险因素评估、个性化目标制定、定向健康教育视频推送、健康数据监测与反馈及游戏化激励等五大模块。12个月随访显示，干预显著促进了心血管风险的整体降低，促进了行为及代谢危险因素的改善。该成果为

Findings from 16-week trial of novel compression patch will be shared for the first time at the 85th Scientific Sessions of the American Diabetes Association, beginning today FREMONT, Calif., June 20, 2025 /PRNewswire/ -- Neodyne Biosciences announced that new clinical data demonstrate the company's embrace® Active Site Care compression patch promotes significant improvement in established lipohypertrophy (LH) among individuals with type 1 diabetes (T1DM). The data also establish injection-site

首款！FDA批准创新小分子药物Cycle Pharmaceuticals日前宣布，美国FDA批准小分子药物Harliku（nitisinone）片剂用于降低成人尿黑酸尿症（AKU）患者尿液中尿黑酸（HGA）水平。根据新闻稿，Harliku成为首款获得FDA批准用于治疗AKU的药物。AKU是一种极罕见的遗传代谢病，患者体内HGA堆积可引发骨关节炎、褐黄病（ochronosis），以及肾脏和心脏并发症等严重问题。Harliku这次的获批主要基于一项随机研究的结果，共纳入40例AKU患者。研究显示，经过三年治疗，Harliku显著改善了患者的疼痛感、精力和身体功能，评估工具为36项简明健康调查表（SF-36）。无进展生存期延长超3倍！罗氏双抗与ADC组合3期试验亮眼结果公布罗氏（Roche）日前公布其3期SUNMO研究的最新成果。分析显示，其CD20/CD3靶向双特异性抗体Lunsumio（mosunetuzumab）联合CD79b靶向抗体偶联药物（ADC）Polivy（polatuzumab vedotin），在治疗无法进行造血干细胞移植的复发或难治性大B细胞淋巴瘤（R/R LBCL）患者

近日，由三优生物提供抗体药研发CPO，明慧医药研发创新的B7-H3靶向抗体偶联药物MHB088C已正式在中国启动针对难治性小细胞肺癌（SCLC）的III期注册临床试验（CTR20250586）。同时，明慧医药与齐鲁制药就MHB088C达成总额13.45亿元人民币的独家授权合作，创下中国ADC领域又一里程碑！MHB088C是明慧基于自主研发的SuperTopoi™ ADC技术平台打造的创新型B7-H3靶向抗体偶联药物，兼具更强的肿瘤杀伤效力与更优的安全性，显著拓宽了治疗窗口。三优生物有幸通过CPO业务模式助力明慧医药达成这一重要里程碑，协同明慧医药完成了临床前B7-H3抗体药物发现的关键工作。（更多三优ADC研发服务信息请阅读《三优ADC药物研发系统解决方案》）。三优生物CEO郎国竣博士表示：“我们由衷祝贺明慧医药MHB088C实现从科学概念到III期临床的飞跃，并达成与齐鲁制药的战略合作！期待这款中国创新的重磅ADC药物早日上市，为全球患者点燃生命新希望！”关于明慧医药明慧医药是一家处于临床后期阶段的生物制药公司，专注于开发创新药物，以满足肿瘤和自身免疫性疾病领域的未满足医疗需求。依托

Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes CHICAGO, June 20, 2025 /PRNewswire/ -- Findings from two studies reveal advancements in stem cell-derived treatment options to treat type 1 diabetes. Results from the FORWARD study, also simultaneously published in the New England Journal of Medicine (NEJM), evaluating the first and only allogeneic, stem-cell derived, islet cell therapy and a study of genetically modified stem c

Hybrid closed-loop technology effectively helped women stay in target glucose range for longer compared to standard of care CHICAGO, June 20, 2025 /PRNewswire/ -- A new study shows pregnant women with type 1 diabetes stayed in the target blood glucose (blood sugar) range for pregnancy more often with an automated insulin delivery (AID) system (Control-IQ Technology) that is currently available for use—but not approved in pregnancy—compared to standard insulin delivery with injections or open-lo

New Studies Highlight Machine Learning as Potential Early Risk Detection Strategy CHICAGO, June 20, 2025 /PRNewswire/ -- Developments from two studies highlighting the potential for machine learning leveraging artificial intelligence (AI) technology to improve early-stage identification of type 1 diabetes were presented as late-breaking poster sessions at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago. Each year, around 64,000 Americans are diagnosed with typ

Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in Lancet Diabetes & Endocrinology. GALWAY, Ireland and CHICAGO, June 20, 2025 /PRNewswire/ -- Medtronic, a global leader in healthcare technology, will present data at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, highlighting improved glycemic outcomes for individuals with insulin-intensive type 2 diabetes on the MiniMed™ 780G* system under inves

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2 PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesi

New Research Demonstrates Significant Benefits of Simple Dietary Switch for Blood Glucose Control and Long-Term Weight Management CHICAGO, June 20, 2025 /PRNewswire/ -- Consistently replacing diet beverages with water in women with type 2 diabetes may contribute to greater weight loss and increases the likelihood of long-term diabetes remission. The results were presented as a general poster at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago. Everyday, approxi